Val17ile single nucleotide polymorphisms similarly as Ala15Thr could be related to the lower secretory dynamics of PAI-1 secretion - theoretical evidence

Current Molecular Medicine

Volumn 11, Issue 6, 2011, Pages 512-516

  Jankun, J ^a,b,c   Skrzypczak Jankun, E ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Ala15Thr; PAI 1 deficiency; SNP; Val17ile

Indexed keywords

ALANINE; ISOLEUCINE; MUTANT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THREONINE; VALINE;

ARTICLE; BLEEDING; HUMAN; PROTEIN DEFICIENCY; PROTEIN SECRETION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79960290699     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411796268678     Document Type: Article

References (22)

1. Liu YX, Gao F, Wei P, et al. Involvement of molecules related to angiogenesis, proteolysis and apoptosis in implantation in rhesus monkey and mouse. Contraception 2005; 71: 249-62.
2. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-52.
3. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003; 9: 1545-64.
4. Pawse AR, Tarachand U. Clot lysis: role of plasminogen activator inhibitors in haemostasis and therapy. Indian J Exp Biol 1997; 35: 545-52.
5. Repine T, Osswald M. Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review. Clin Appl Thromb Hemost 2004; 10: 293-6.
6. Meas T, Deghmoun S, Chevenne D, Gaborit B, Alessi MC, Levy-Marchal C. Plasminogen activator inhibitor type-1 is an independent marker of metabolic disorders in young adults born small for gestational age. J Thromb Haemost 2010; 8: 2608-13.
7. Jankun J, Aleem AM, Selman SH, et al. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. Int J Mol Med 2007; 20: 683-7.
8. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90: 204-8.
9. Lopes C, Dina C, Durand E, Froguel P. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 2003; 46: 1284-90.
10. Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008; 14: 1255-60.
11. Zhang ZY, Wang ZY, Dong NZ, Bai X, Zhang W, Ruan CG. A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide. Blood Coagul Fibrinolysis 2005; 16: 79-84.
12. Jankun J, Skrzypczak-Jankun E. Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1. Exp Ther Med 2010; 1: 575-7.
13. Hon LS, Zhang Y, Kaminker JS, Zhang Z. Computational prediction of the functional effects of amino acid substitutions in signal peptides using a model-based approach. Hum Mutat 2009; 30: 99-106.
14. DeLano WL (2002) The PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA, USA, http://www.pymol.org.
15. Sharp AM, Stein PE, Pannu NS, et al. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 1999; 7: 111-18.
16. Stout TJ, Graham H, Buckley DI, Matthews DJ. Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 2000; 39: 8460-9.
17. Tucker HM, Mottonen J, Goldsmith EJ, Gerard RD. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol 1995; 2: 442-5.
18. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997; 77: 730-4.
19. Grancha S, Estelles A, Tormo G, et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999; 81: 516-21.
20. Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 1995; 14: 2969-77.
21. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH, Jankun J. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2003; 2: 19-28.
22. Agren A, Wiman B, Schulman S. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis 2007; 18: 657-60.